Azenta, Inc. Fiscal 2022 Form 10-K Summary
Business context and reporting period
Azenta is a global life sciences sample management, automated storage, cold-chain, and genomic services provider. The filing covers the fiscal year ended September 30, 2022, with comparisons to fiscal 2021 and 2020. The semiconductor automation business was sold to Thomas H. Lee Partners on February 1, 2022, for $2.9 billion in cash and is presented as discontinued operations. Continuing operations comprise Life Sciences Products and Life Sciences Services.
Key financial metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $555.5 million | $513.7 million | Up 8% |
| Gross profit | $255.6 million | $243.8 million | Up $11.8 million |
| Gross margin | 46.0% | 47.5% | Down 1.5 points |
| Operating loss | $24.7 million | $31.1 million | Improved $6.4 million |
| Loss from continuing operations | $11.3 million | $28.9 million | Improved $17.6 million |
| Net income | $2.133 billion | $110.7 million | Includes divestiture gain |
| Basic net income per share | $28.48 | $1.49 | Includes discontinued operations |
- Life Sciences Products revenue was $199.2 million, essentially flat year over year; adjusted operating income was $12.2 million versus $23.1 million.
- Life Sciences Services revenue increased 13% to $356.3 million, including 18% growth in sample repository solutions and 11% growth in genomic services. Adjusted operating income was $16.8 million versus $22.7 million.
- Total segment adjusted operating income declined to $21.8 million from $45.8 million, and adjusted segment operating margin declined to 4% from 9%.
- Research and development expense increased to $27.5 million from $22.4 million. Selling, general and administrative expense was essentially flat at $252.1 million.
- Interest income increased to $20.3 million from $0.6 million, primarily from investing divestiture proceeds. Interest expense was $4.6 million, and the company recorded a $0.6 million loss on debt extinguishment.
- Cash, restricted cash, and marketable securities totaled $2.305 billion at September 30, 2022, including $1.264 billion of marketable securities. Cash, cash equivalents, and restricted cash totaled $1.041 billion.
- Operating cash flow was a use of $466.0 million, principally because of $431.6 million of divestiture-related taxes and $52.5 million of divestiture fees. Investing cash flow was $1.466 billion, including $2.939 billion of divestiture proceeds and $1.3 billion of net marketable-securities investments.
- Capital expenditures were $73.4 million, and acquisitions and related investments used $125.9 million, including $84.8 million for Barkey.
- The former $200 million term loan was extinguished on February 1, 2022. The revolving credit facility was terminated, and the company reported no outstanding debt at year-end.
- Goodwill was $513.6 million and net intangible assets were $178.4 million. A quantitative year-end impairment test was performed after the stock-price decline; no impairment was recorded.
Material changes versus the prior comparable period
- The company completed its strategic exit from semiconductor automation. FY2022 discontinued-operations income was $2.144 billion, including a $2.562 billion gain on sale, compared with $139.6 million in FY2021.
- Continuing-operations revenue grew, led by Life Sciences Services, but margin pressure from inflation, unfavorable product mix, currency effects, and infrastructure investments reduced profitability.
- COVID-related revenue declined to approximately $22 million from $53 million, particularly affecting consumables and instruments demand.
- On July 1, 2022, Azenta acquired Barkey, a controlled-rate thawing-device provider, for approximately $84.8 million.
- On October 3, 2022, after year-end, Azenta acquired B Medical Systems for an initial cash purchase price of $422 million, with potential contingent consideration of approximately $50 million. The company had prepaid $43.1 million of B Medical debt and recorded approximately $381 million of restricted cash before closing.
- Foreign-exchange translation reduced accumulated other comprehensive income by $169.3 million in FY2022. A cross-currency swap generated a $124.8 million derivative asset and an after-tax $93.0 million gain in other comprehensive income.
Guidance, outlook, commentary, risks, and unusual items
Management expects continued growth in life sciences products and services through internal development, acquired businesses, and potential future acquisitions, but the filing does not provide specific revenue, earnings, or margin guidance. Management states that liquidity is adequate for working capital, debt service, financing, and capital expenditures for the next twelve months.
- Key risks include macroeconomic weakness, inflation, rising interest rates, COVID-19 disruptions, supply-chain constraints, foreign-exchange volatility, international trade restrictions, customer spending reductions, and competition.
- Approximately 33% of FY2022 revenue was generated outside North America. About $867.6 million of cash, cash equivalents, and restricted cash was held outside the United States at year-end.
- The company approved a $1.5 billion share-repurchase authorization on November 4, 2022 and expected to enter into an accelerated share-repurchase agreement for up to $500 million. No repurchases had occurred through the filing date.
- Non-cancelable commitments totaled $66.6 million, including $55.6 million of inventory purchase orders and $10.9 million of information-technology commitments.
- A tariff matter resulted in a $5.9 million payment during FY2022; a $2.8 million tariff accrual remained at year-end. Customs authorities may determine that additional tariffs are owed.
- The company is subject to ordinary-course litigation and indemnification claims related to prior divestitures. Management does not currently expect these matters to materially affect consolidated results, but outcomes remain uncertain.
- The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. Goodwill impairment valuation was identified as a critical audit matter.
Important facts for investors to verify
- Separate continuing-operations performance from the $2.6 billion divestiture gain and other discontinued-operations results.
- Assess whether Life Sciences Services growth can offset declining adjusted margins and weaker Life Sciences Products profitability.
- Review the post-year-end B Medical acquisition, purchase-price allocation, contingent consideration, debt repayment, and integration costs.
- Monitor deployment of the $1.5 billion repurchase authorization versus acquisitions, operating needs, and foreign cash restrictions.
- Evaluate sensitivity of goodwill and intangible assets to revenue growth, gross margins, operating expenses, discount rates, and market conditions.
- Verify cash availability and currency exposure, including the $1.3 billion marketable-securities portfolio, $867.6 million of foreign-held cash and restricted cash, and the February 2023 cross-currency swap maturity.
- Track potential additional tariff liabilities, legal and indemnification claims, tax examinations, and the company’s $1.7 million of unrecognized tax benefits and related interest.